image75
image76
  • Home
    • Mission
    • Leadership
    • Advisors
  • Platform
    • Pipeline
    • JNTX-101
    • JNTX-104
  • News & Events
  • Contact
    • Home
    • About
      • Mission
      • Leadership
      • Advisors
    • Platform
    • Pipeline
      • Pipeline
      • JNTX-101
      • JNTX-104
    • News & Events
    • Contact

  • Home
  • Platform
  • News & Events
  • Contact


JNTX-104 Collaboration

Consistent with January’s business model, the company has entered into a collaboration with world-renowned cancer research and treatment center, City of Hope.


January scientists are applying the CAN platform to a CoH therapeutic candidate for the treatment of AML

image77

Acute Myeloid Leukemia (AML)

AML BACKGROUND

  • AML is a cancer of the blood and bone marrow which can progress rapidly if left untreated 
  • 60-70% of AML patients initially respond to chemotherapy, however AML is characterized by a high degree of relapse
  • Patients with FLT3-ITD mutations (20-30% of cases) have a higher chance of relapse
  • Overall, AML 5-year survival rate is only ~30%


UNMET NEED

  • Novel and more effective treatments are needed for the treatment of AML 
  • JNTX-104 has the potential for accelerated approval 

Copyright © 2021 January Therapeutics - All Rights Reserved.